JP7844491B2 - ヒドロキシヘテロシクロアルカン-カルバモイル誘導体 - Google Patents

ヒドロキシヘテロシクロアルカン-カルバモイル誘導体

Info

Publication number
JP7844491B2
JP7844491B2 JP2023547852A JP2023547852A JP7844491B2 JP 7844491 B2 JP7844491 B2 JP 7844491B2 JP 2023547852 A JP2023547852 A JP 2023547852A JP 2023547852 A JP2023547852 A JP 2023547852A JP 7844491 B2 JP7844491 B2 JP 7844491B2
Authority
JP
Japan
Prior art keywords
pyran
hydroxy
carboxamide
hydroxymethyl
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506182A5 (cg-RX-API-DMAC7.html
JP2024506182A (ja
Inventor
ボリ マーティン
ガットフィールド ジョン
グリソストミ コリンナ
レメン ルボス
ザーガー クリストフ
ツムブルン コルネリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of JP2024506182A publication Critical patent/JP2024506182A/ja
Publication of JP2024506182A5 publication Critical patent/JP2024506182A5/ja
Application granted granted Critical
Publication of JP7844491B2 publication Critical patent/JP7844491B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
JP2023547852A 2021-02-09 2022-02-08 ヒドロキシヘテロシクロアルカン-カルバモイル誘導体 Active JP7844491B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2021053084 2021-02-09
EPPCT/EP2021/053084 2021-02-09
PCT/EP2022/052948 WO2022171594A1 (en) 2021-02-09 2022-02-08 Hydroxyheterocycloalkane-carbamoyl derivatives

Publications (3)

Publication Number Publication Date
JP2024506182A JP2024506182A (ja) 2024-02-09
JP2024506182A5 JP2024506182A5 (cg-RX-API-DMAC7.html) 2025-02-17
JP7844491B2 true JP7844491B2 (ja) 2026-04-13

Family

ID=80445748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547852A Active JP7844491B2 (ja) 2021-02-09 2022-02-08 ヒドロキシヘテロシクロアルカン-カルバモイル誘導体

Country Status (13)

Country Link
US (1) US12304902B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291556B1 (cg-RX-API-DMAC7.html)
JP (1) JP7844491B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145111A (cg-RX-API-DMAC7.html)
CN (1) CN116806219A (cg-RX-API-DMAC7.html)
AU (1) AU2022221092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207214A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002322A1 (cg-RX-API-DMAC7.html)
ES (1) ES3032987T3 (cg-RX-API-DMAC7.html)
IL (1) IL304923A (cg-RX-API-DMAC7.html)
TW (1) TW202246248A (cg-RX-API-DMAC7.html)
WO (1) WO2022171594A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202308643B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
MA56883B1 (fr) 2019-08-15 2025-04-30 Idorsia Pharmaceuticals Ltd Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh) 2019-08-29 2024-09-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
US12291520B2 (en) 2020-11-02 2025-05-06 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1-carbamoyl derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519625A (ja) 2017-05-12 2020-07-02 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 疾患の予防および治療用の化合物およびその使用
WO2020210308A1 (en) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
JP2023547241A (ja) 2020-11-02 2023-11-09 イドーシア ファーマシューティカルズ リミテッド ガレクチン-3を阻害する2-ヒドロキシシクロアルカン-1-カルバモイル誘導体
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド 2-ヒドロキシシクロアルカン-1-カルバモイル誘導体
JP7612669B2 (ja) 2019-08-29 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド アルファ-d-ガラクトピラノシド誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (cg-RX-API-DMAC7.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
CN109563119A (zh) 2016-07-12 2019-04-02 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
CA3062649A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
JP2021501180A (ja) 2017-10-31 2021-01-14 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 全身インスリン抵抗性障害の治療のためのセレノガラクトシド化合物およびその使用
CN113366007A (zh) 2018-10-15 2021-09-07 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂
CN113286632A (zh) 2018-10-15 2021-08-20 格莱克特生物技术公司 半乳糖凝集素的半乳糖苷抑制剂前药
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
JP7674276B2 (ja) 2019-07-03 2025-05-09 ガレクト バイオテック エービー ガレクチンの新規なガラクトシド阻害剤
CA3143078A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
KR102863667B1 (ko) 2019-08-09 2025-09-23 이도르시아 파마슈티컬스 리미티드 (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
WO2022184755A1 (en) 2021-03-03 2022-09-09 Idorsia Pharmaceuticals Ltd Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519625A (ja) 2017-05-12 2020-07-02 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 疾患の予防および治療用の化合物およびその使用
WO2020210308A1 (en) 2019-04-10 2020-10-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
JP7604457B2 (ja) 2019-08-15 2024-12-23 イドルシア・ファーマシューティカルズ・リミテッド 2-ヒドロキシシクロアルカン-1-カルバモイル誘導体
JP7612669B2 (ja) 2019-08-29 2025-01-14 イドルシア・ファーマシューティカルズ・リミテッド アルファ-d-ガラクトピラノシド誘導体
JP2023547241A (ja) 2020-11-02 2023-11-09 イドーシア ファーマシューティカルズ リミテッド ガレクチン-3を阻害する2-ヒドロキシシクロアルカン-1-カルバモイル誘導体

Also Published As

Publication number Publication date
CN116806219A (zh) 2023-09-26
EP4291556C0 (en) 2025-04-23
EP4291556B1 (en) 2025-04-23
WO2022171594A1 (en) 2022-08-18
CL2023002322A1 (es) 2024-03-08
KR20230145111A (ko) 2023-10-17
CA3207214A1 (en) 2022-08-18
IL304923A (en) 2023-10-01
ZA202308643B (en) 2026-03-25
ES3032987T3 (en) 2025-07-29
AU2022221092A1 (en) 2023-09-21
US20240124427A1 (en) 2024-04-18
TW202246248A (zh) 2022-12-01
JP2024506182A (ja) 2024-02-09
US12304902B2 (en) 2025-05-20
EP4291556A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
KR102832308B1 (ko) 2-히드록시시클로알칸-1-카르바모일 유도체
JP7834746B2 (ja) ガレクチン-3を阻害する2-ヒドロキシシクロアルカン-1-カルバモイル誘導体
EP4291556B1 (en) Hydroxyheterocycloalkane-carbamoyl derivatives
JP7612663B2 (ja) (2-アセタミジル)チオ-ベータ-d-ガラクトピラノシド誘導体
JP7757399B2 (ja) アルファ-d-ガラクトピラノシドのスピロ誘導体
HK40101885B (en) Hydroxyheterocycloalkane-carbamoyl derivatives
HK40101885A (en) Hydroxyheterocycloalkane-carbamoyl derivatives
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные
CN116745282A (zh) 抑制2-羟环烷-1-氨甲酰基衍生物的半乳糖凝集素-3
EA050798B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные, ингибирующие галектин-3
HK40071801B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
HK40071801A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
EA048291B1 (ru) 2-гидроксициклоалкан-1-карбамоильные производные

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260401

R150 Certificate of patent or registration of utility model

Ref document number: 7844491

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150